Scope and Claim-Chart Analysis of US Patent 9,238,076: Exendin-4 Sustained-Release Composition Using Purified 50:50 DL PLG 4A With ≤0.1 mL/g Pore Volume

US 9,238,076 is a focused US patent covering a specific depot-style exendin-4 composition for Type 2 diabetes built on a defined poly(lactide-co-glycolide) (PLG) polymer grade and tight physicochemical constraints that drive a target in vivo release shape. The independent claim is claim 1, with dependent claim fallbacks that narrow to higher exendin-4 loading (claim 3), specific polymer inherent viscosity (claim 4), a defined injection vehicle (claim 5), and injection administration (claim 6). A generic or biosimilar entry risk assessment should treat the patent as a “device-like” release-profile patent: infringement turns on matching the claimed formulation parameters and the resulting Cmax/Cave release profile, not simply on “exendin-4 plus a polymer.”

What does US 9,238,076 protect: composition claims for exendin-4 sustained release in PLG?

Short answer: Claim 1 protects a composition “suitable for the treatment of Type-2 diabetes” defined by (i) purified 50:50 DL PLG 4A polymer, (ii) exendin-4 at ~3% to ~5% w/w, (iii) sucrose at ~2% w/w, and (iv) a mercury intrusion porosimetry pore volume ≤0.1 mL/g that yields a release profile where Cmax/Cave ≤ 3 over the release period.

Independent claim 1: the full protected scope

Claim 1 is structured as a formulation with built-in functional release constraints:

Polymer identity and purity

“purified 50:50 DL PLG 4A polymer”
The “50:50 DL” element is a composition ratio and stereochemistry shorthand for lactide:glycolide at 50:50 and the DL stereochemical form.
“PLG 4A” is the key narrowing identifier, which typically signals a specific polymer specification (grade/processing).

Active and excipient loading windows

Exendin-4: about 3% to about 5% (w/w)
Sucrose: about 2% (w/w)

Porosity constraint by mercury intrusion porosimetry

“total pore volume … about 0.1 mL/g or less”
This is not just “low porosity”; it is quantitatively defined via a specific measurement method.

Functional release-profile constraint

Provides a release profile with a Cmax/Cave ratio about 3 or less
The constraint ties the formulation to a pharmacokinetic release shape across the release period.

Therapeutic context

“composition suitable for the treatment of Type-2 diabetes”
This does not by itself narrow to an approved indication, but it supports an intended-use frame.

Key legal claim-interpretation pressures

From an infringement and validity perspective, claim 1 has three high-leverage elements:

“Consisting essentially of”: limits the composition to the listed components (polymer, exendin-4, sucrose) plus only those additional components that do not materially affect the basic and novel characteristics.
“Purified 50:50 DL PLG 4A”: can become a differentiator for competitors using different PLG grades, different end groups, different manufacturing impurities, different molecular weight distributions, or different polymer identifiers.
Functional metrics (≤0.1 mL/g pore volume and Cmax/Cave ≤ 3): these are measurable and can be used both for infringement testing and for claim validity (enablement, definiteness, and written description).

How do claims 2-6 narrow scope: method, dosage form, vehicle, and administration?

Short answer: Claims 2 and 6 cover treatment via administering the claimed composition by injection. Claims 3-5 narrow the composition by exendin-4 loading, polymer inherent viscosity, and a defined injection vehicle composition.

Claim 2 (method of treatment)

“A method of treating … Type 2 diabetes” by administering a therapeutically effective amount of the claim 1 composition.

Scope impact: If a composition falls within claim 1, claim 2 captures downstream use by administering it to patients. For generic entry, even if the product label or intended use differs, actual medical administration can still trigger method claim exposure if the claims are interpreted as covering administering the claimed composition.

Claim 3 (exendin-4 loading at ~5% w/w)

Narrows claim 1 to exendin-4 at about 5% (w/w).

Scope impact: This is a fallback that strengthens the patent if prior art or non-infringing variants primarily sit at lower exendin-4 loadings (e.g., ~3–3.5%).

Claim 4 (polymer inherent viscosity 0.3–0.5 dL/g)

Limits polymer inherent viscosity to 0.3 to 0.5 dL/g.

Scope impact: Many competitors will use PLG with different molecular weight distributions (which shift inherent viscosity). This claim provides a second line of infringement and defense.

Claim 5 (defined injection vehicle formulation)

Composition is suspended in a vehicle containing:
- sodium carboxymethylcellulose at 3.0% (w/v)
- sodium chloride at 0.9% (w/v)
- Polysorbate 20 NF (Tween 20) at 0.1% (v/v)
- water

Scope impact: This claim narrows to a specific manufacturing-ready suspension medium. Infringement for the formulation can depend on whether the competitor’s vehicle differs in a way that is argued to materially affect the basic and novel characteristics. Claim 5 is a concrete “formulation kit” element that can be avoided by vehicle substitution, depending on claim construction of “consisting essentially of.”

Claim 6 (administration by injection)

Method claim 2 where the composition is administered by injection.

Scope impact: If a competitor uses alternative administration routes, claim 6 narrows their risk. For most depot exendin-4 products, injection is the typical route.

What formulation parameters drive infringement risk under claim 1?

Short answer: Infringement is most sensitive to (1) the exact PLG 4A grade/purification, (2) exendin-4 and sucrose loadings, and (3) the pore volume and resulting Cmax/Cave release metric. If any of these are not met, competitors have multiple carve-out levers.

Parameter-by-parameter risk map

Claim element	Claimed limit	Why it matters for infringement
Polymer identity	purified 50:50 DL PLG 4A	A different PLG grade or non-PLG-4A identity is a plausible non-infringement trigger.
Polymer purity/characterization	“purified” (no numerical spec in provided text)	Competitors can argue non-matching due to impurity profile, processing method, residual monomers, or solvent remnants.
Exendin-4 loading	about 3% to about 5% (w/w)	Competitors outside the window avoid literal coverage; “about” creates tolerance, often litigation-tested.
Sucrose loading	about 2% (w/w)	A stabilizer level can be substituted; but “consisting essentially of” constraints limit allowable changes.
Mercury intrusion total pore volume	about 0.1 mL/g or less	Quantitative; can be measured on finished depots or intermediate product.
Release profile metric	Cmax/Cave about 3 or less	Functional; requires PK study matching the “period of release.”
Composition structure	“consisting essentially of”	Limits additional excipients; affects whether a competitor’s vehicle or residuals are excluded.

How does the Cmax/Cave ≤ 3 functional limitation affect testing and enforcement?

Short answer: This is a PK-release shape constraint that can become the central battleground: competitors can argue their product releases exendin-4 differently in a way that raises Cmax/Cave above 3, even if it uses similar polymer and loadings.

What “period of release” implies in practice

Even without the patent text defining the release period, the infringement testing would typically require:

define a release window (time interval)
measure serum exendin-4 concentration-time profile during that window
compute Cmax and Cave (average concentration over the release period)
verify the Cmax/Cave ratio ≤ 3

Enforcement profile

For plaintiff-side enforcement, the patent can be asserted by producing a product matched to the claim boundaries and running PK in a relevant model.
For defense, non-infringement arguments can target:
- different in vivo release timing (shifts Cmax upward relative to Cave)
- different depot porosity affecting diffusion/erosion behavior
- different particle morphology even with the same nominal polymer and loadings

How do polymer inherent viscosity (claim 4) and pore volume (claim 1) interrelate?

Short answer: Polymer inherent viscosity is a proxy for molecular weight; molecular weight affects degradation kinetics and, indirectly, depot porosity and release. The patent treats pore volume (directly) and inherent viscosity (narrower dependent fallback) as separate measurable parameters.

If a competitor uses PLG with inherently different molecular weights, they may still engineer pore volume and PK by process control, but claim 4 is an additional narrow hook for the patent holder.
If a competitor matches pore volume and PK but uses a different inherent viscosity, claim 4 may be avoided while claim 1 could still be asserted if “purified 50:50 DL PLG 4A” and the Cmax/Cave metric are met.

What does “purified 50:50 DL PLG 4A” likely mean for claim construction?

Short answer: “Purified” and the specific identifier “PLG 4A” are likely to become central to both literal infringement and non-infringement defenses focused on material sourcing and grade differences.

Typical battlefield facts that determine “purified”

Even without the full patent specification in the prompt, “purified” generally invites scrutiny on:

residual monomer content or oligomer profile
impurities from polymer synthesis
residual solvent levels
batch-to-batch specifications associated with PLG 4A

Why PLG grade naming matters

Competitors usually can source multiple PLG families. The more the patent treats “PLG 4A” as a defined spec, the harder it becomes to design around by using “similar” PLG.

How strong is the patent estate for exendin-4 depot compositions based on these claim features?

Short answer: On the claim language alone, US 9,238,076 is strong as a composition-and-functional-release patent with multiple dependent fallbacks. Strength depends on whether claim 1’s “consisting essentially of,” PLG 4A specificity, pore volume measurement, and Cmax/Cave threshold are supported by robust disclosure.

Strength indicators in the claims

Multiple quantitative constraints (exendin-4 w/w, sucrose w/w, pore volume ≤0.1 mL/g, inherent viscosity range, Cmax/Cave ≤3).
A functional PK-release metric narrows scope to a release pattern rather than general sustained release.
“Consisting essentially of” reduces latitude for substitutes that add other excipients.

Potential vulnerability points

If the patent specification defines “about” ranges broadly, validity risk exists if it is not supported with examples across the claimed boundaries.
If the “Cmax/Cave” release period and calculation method are not clearly tied to a reproducible protocol, definiteness and enablement become litigation issues.

What generic entry risks exist for products attempting to compete with this depot formulation?

Short answer: The risk is highest for depot products that use:

the same (or equivalent) PLG 4A polymer grade,
similar exendin-4 and sucrose loadings, and
engineered porosity and release kinetics achieving Cmax/Cave ≤3.

Design-around vectors

Because claim 1 is tied to both formulation composition and functional release outcome, there are three principal design-around strategies:

Polymer change

Use different PLG grade, different inherent viscosity, or different polymer identity than “purified 50:50 DL PLG 4A.”

Porosity manipulation

Target pore volume >0.1 mL/g (if feasible while maintaining safety and efficacy).

Release-shape shifting

Adjust formulation and manufacturing to increase Cmax relative to average concentration so Cmax/Cave exceeds 3.

Vehicle substitution (claim 5) is a narrower strategy that may help with claim 5 specifically but does not necessarily avoid claim 1 if vehicle components are excluded or permitted under “consisting essentially of.”

How do dependent claims affect litigation strategy and settlement leverage?

Short answer: Claims 3-5 provide multiple independent narrowing paths that can preserve enforceability even if accused products miss some parameters.

If an accused product uses exendin-4 slightly below 5% w/w, claim 1 might still be asserted; claim 3 would not help.
If polymer inherent viscosity falls outside 0.3–0.5 dL/g, claim 4 fails; claim 1 still may stand if the PLG 4A identity and pore volume/Cmax-Cave are met.
If the accused formulation uses a different suspension vehicle, claim 5 may fail; claim 1 could still be asserted depending on whether vehicle components are considered part of the “composition” under “consisting essentially of.”

This layered structure typically increases the patent holder’s settlement leverage because defendants must clear multiple parameter barriers.

Key Takeaways

US 9,238,076 claim 1 protects an exendin-4 depot composition for Type 2 diabetes that is defined by specific material identity (purified 50:50 DL PLG 4A), exact loading windows (exendin-4 ~3–5% w/w; sucrose ~2% w/w), a quantitative pore-volume limit (≤0.1 mL/g by mercury intrusion porosimetry), and a functional PK constraint (Cmax/Cave ≤3 over the release period).
The independent claim’s “consisting essentially of” structure limits allowable additional components; vehicle changes may avoid dependent claim 5 but not necessarily claim 1.
Dependent claims add enforceable fallbacks: exendin-4 at ~5% (claim 3), polymer inherent viscosity 0.3–0.5 dL/g (claim 4), a defined suspension vehicle (claim 5), and injection administration (claim 6).
The highest infringement risk for competitors is matching both the quantitative formulation parameters and the resulting release-shape metric (Cmax/Cave). The highest design-around probability is changing polymer grade/identity or engineering release kinetics so Cmax/Cave exceeds 3.

FAQs

1) Does changing sucrose level avoid infringement of US 9,238,076?
Yes, if sucrose is moved outside “about 2% (w/w)” while also respecting “consisting essentially of” constraints and maintaining non-infringement on the pore-volume and Cmax/Cave metrics.

2) Can a competitor avoid claim 5 by using a different suspension excipient package?
It may avoid claim 5 specifically, but claim 1 can still be asserted if the “composition” is found to include those vehicle components within “consisting essentially of” and if claim 1’s other constraints are met.

3) What is the main test plan to assess infringement for the Cmax/Cave limitation?
A PK study that defines the “period of release,” then calculates Cmax and Cave over that same interval to confirm whether Cmax/Cave is ≤3.

4) If a product uses PLG with the right inherent viscosity but not “PLG 4A,” is it still at risk?
Yes. Claim 4 is only a dependent fallback. If the accused product still meets “purified 50:50 DL PLG 4A,” pore volume, exendin-4 and sucrose loadings, and Cmax/Cave ≤3, claim 1 can still be implicated.

5) Does the method-of-treatment claim require the same release profile proof?
If the method claim is asserted through infringement of the claimed composition, the same formulation and functional release characteristics that define claim 1 are relevant to establishing that the administered product is the claimed composition.

References (APA)

No sources were provided in the prompt for US Patent 9,238,076 text, prosecution history, or Orange Book/FDA status; therefore no external citations are included.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1734971	⤷ Start Trial	16/2012	Austria	⤷ Start Trial
European Patent Office	1734971	⤷ Start Trial	122012000028	Germany	⤷ Start Trial
European Patent Office	1734971	⤷ Start Trial	C300526	Netherlands	⤷ Start Trial
European Patent Office	1734971	⤷ Start Trial	CA 2012 00015	Denmark	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,238,076

Summary for Patent: 9,238,076